JP2016502974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502974A5 JP2016502974A5 JP2015545914A JP2015545914A JP2016502974A5 JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5 JP 2015545914 A JP2015545914 A JP 2015545914A JP 2015545914 A JP2015545914 A JP 2015545914A JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5
- Authority
- JP
- Japan
- Prior art keywords
- gdc
- combination
- cancer
- acceptable salt
- mehd7945a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734796P | 2012-12-07 | 2012-12-07 | |
| US61/734,796 | 2012-12-07 | ||
| US201361888892P | 2013-10-09 | 2013-10-09 | |
| US61/888,892 | 2013-10-09 | ||
| PCT/US2013/073914 WO2014089570A1 (en) | 2012-12-07 | 2013-12-09 | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502974A JP2016502974A (ja) | 2016-02-01 |
| JP2016502974A5 true JP2016502974A5 (enExample) | 2016-12-15 |
Family
ID=49885413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545914A Pending JP2016502974A (ja) | 2012-12-07 | 2013-12-09 | Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9566334B2 (enExample) |
| EP (1) | EP2928488A1 (enExample) |
| JP (1) | JP2016502974A (enExample) |
| KR (1) | KR20150092760A (enExample) |
| CN (1) | CN104968363A (enExample) |
| BR (1) | BR112015013196A2 (enExample) |
| CA (1) | CA2894153A1 (enExample) |
| HK (1) | HK1211218A1 (enExample) |
| MX (1) | MX2015007054A (enExample) |
| RU (1) | RU2015127037A (enExample) |
| WO (1) | WO2014089570A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2901126C (en) * | 2013-02-25 | 2022-01-25 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| CA3032233C (en) * | 2016-08-10 | 2021-09-14 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising akt protein kinase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| SG10201402742YA (en) * | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| KR20140022053A (ko) * | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법 |
| WO2012177925A1 (en) * | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| EP2780469A1 (en) * | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2788752B1 (en) * | 2011-12-05 | 2018-10-03 | Pierian Holdings, Inc. | Method of therapy selection for patients with lung cancer |
-
2013
- 2013-12-09 HK HK15112070.1A patent/HK1211218A1/xx unknown
- 2013-12-09 KR KR1020157018031A patent/KR20150092760A/ko not_active Withdrawn
- 2013-12-09 CA CA2894153A patent/CA2894153A1/en not_active Abandoned
- 2013-12-09 BR BR112015013196-4A patent/BR112015013196A2/en not_active Application Discontinuation
- 2013-12-09 RU RU2015127037A patent/RU2015127037A/ru not_active Application Discontinuation
- 2013-12-09 WO PCT/US2013/073914 patent/WO2014089570A1/en not_active Ceased
- 2013-12-09 MX MX2015007054A patent/MX2015007054A/es unknown
- 2013-12-09 US US14/649,889 patent/US9566334B2/en not_active Expired - Fee Related
- 2013-12-09 CN CN201380072029.4A patent/CN104968363A/zh active Pending
- 2013-12-09 EP EP13814710.3A patent/EP2928488A1/en not_active Withdrawn
- 2013-12-09 JP JP2015545914A patent/JP2016502974A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509659A5 (enExample) | ||
| JP2014512354A5 (enExample) | ||
| RU2013148728A (ru) | Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения | |
| MX2021002321A (es) | Nuevos metodos. | |
| JP2014512355A5 (enExample) | ||
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2014509657A5 (enExample) | ||
| RU2012156903A (ru) | Способы комбинированной терапии для лечения пролиферативных заболеваний | |
| Jackisch et al. | Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| JP2016528162A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| NZ598137A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| RU2016141569A (ru) | Комбинации | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| JP2016535756A5 (enExample) | ||
| MY178919A (en) | Antibody drug conjugates (adc) that bind to flt3 proteins | |
| JP2019504105A5 (enExample) | ||
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| Spagnolo et al. | Upcoming strategies for the treatment of metastatic melanoma | |
| MX2015002301A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7. | |
| JP2021512105A5 (enExample) | ||
| JOP20200015A1 (ar) | توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين |